Methodologies in Biosimilar Product Development (Chapman & Hall/crc Biostatistics Series)

個数:
電子版価格
¥10,190
  • 電子版あり

Methodologies in Biosimilar Product Development (Chapman & Hall/crc Biostatistics Series)

  • 提携先の海外書籍取次会社に在庫がございます。通常3週間で発送いたします。
    重要ご説明事項
    1. 納期遅延や、ご入手不能となる場合が若干ございます。
    2. 複数冊ご注文の場合、分割発送となる場合がございます。
    3. 美品のご指定は承りかねます。

    ●3Dセキュア導入とクレジットカードによるお支払いについて
  • 【入荷遅延について】
    世界情勢の影響により、海外からお取り寄せとなる洋書・洋古書の入荷が、表示している標準的な納期よりも遅延する場合がございます。
    おそれいりますが、あらかじめご了承くださいますようお願い申し上げます。
  • ◆画像の表紙や帯等は実物とは異なる場合があります。
  • ◆ウェブストアでの洋書販売価格は、弊社店舗等での販売価格とは異なります。
    また、洋書販売価格は、ご注文確定時点での日本円価格となります。
    ご注文確定後に、同じ洋書の販売価格が変動しても、それは反映されません。
  • 製本 Paperback:紙装版/ペーパーバック版/ページ数 380 p.
  • 言語 ENG
  • 商品コード 9781032071800
  • DDC分類 615.19

Full Description

Methodologies for Biosimilar Product Development covers the practical and challenging issues that are commonly encountered during the development, review, and approval of a proposed biosimilar product. These practical and challenging issues include, but are not limited to the mix-up use of interval hypotheses testing (i.e., the use of TOST) and confidence interval approach, a risk/benefit assessment for non-inferiority/similarity margin, PK/PD bridging studies with multiple references, the detection of possible reference product change over time, design and analysis of biosimilar switching studies, the assessment of sensitivity index for assessment of extrapolation across indications without collecting data from those indications not under study, and the feasibility and validation of non-medical switch post-approval.

Key Features:

Reviews withdrawn draft guidance on analytical similarity assessment.
Evaluates various methods for analytical similarity evaluation based on FDA's current guidelines.
Provides a general approach for the use of n-of-1 trial design for assessment of interchangeability.
Discusses the feasibility and validity of the non-medical switch studies.
Provides innovative thinking for detection of possible reference product change over time.

This book embraces innovative thinking of design and analysis for biosimilar studies, which are required for review and approval of biosimilar regulatory submissions.

Contents

Preface. 1. Biosimilar Product Development. 2. CMC Consideration for Quality. 3. Quality by Design. 4. Stability Studies. 5. Two One-sided Tests Versus Confidence Interval Approach. 6. Equivalence Test with Flexible Margin. 7. mQR Method for Analytical Similarity Evaluation. 8. PK/PD Bridging Studies. 9. Clinical Strategy for Non-inferiority/Similarity Margin Selection. 10: Design and Analysis of Biosimilar Switching Studies. 11: Detection of Reference Product Change. 12. Sensitivity Analysis for Assessment of Extrapolation Across Indications. 13. Design and Analysis of Non-medical Switch. 14. Case Studies. References. Subject Index.

最近チェックした商品